BioSpace News Archive

10 Brazilian centers in São Paulo, Brasilia, Presidente Prudente, Sao José do Rio Preto, Varginha, Salvador de Bahia, Criciùma

Alzheimer’s (including MCI)-focused research which reports on the effects of COVID-19 and insights surrounding the new diagnostic agent, TAUVID™

Surgeon’s performance using AR+ for a total knee replacement operation marks a further milestone in advanced surgery Vuzix to host webinar for smart glasses in medical use cases during and beyond the COVID-19 pandemic [02-September-2020] ROCHESTER, N.Y. , Sept. 2, 2020 /PRNewswire/ -- Vuzix® Corporation (NASDAQ: VUZI), (“Vuzix” or, the “Company”), a leadi

Aeglea BioTherapeutics, Inc. announced it will participate in three investor conferences in September 2020, including presenting at the H.C. Wainwright 22nd Annual Global Investment Conference being held virtually on September 14-16, 2020.

ENDRA Life Sciences Inc., the pioneer of Thermo Acoustic Enhanced UltraSound, announced that management will present at the LD 500 Virtual Conference, hosted by LD Micro and taking place virtually September 1 - 4, 2020.

A live webcast of the fireside presentation will be available by visiting the Investors section of the Company’s website at https://ir.radiuspharm.com/events-and-presentations.

Slayback Pharma, LLC announced today that it has received final approval for Icatibant Injection 30 mg/3 ml (10 mg/ml) in a Prefilled Syringe - a generic equivalent of Firazyr.

Supernus Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that the Company’s management will present an overview and update, as well as host investor meetings, at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020 at 9:20 a.m. ET.

SHINE Medical Technologies LLC, a nuclear technology company focused on becoming the world’s leading producer of medical isotopes, announced that it has closed an $80-million Series C financing.

— Tabrecta is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14) — Tabrecta is the fourth molecule discovered by Incyte scientists to be approved by the FDA — Novartis has exclusive worldwide development and commercialization rights to Tabrecta WILMINGTON, Del.--( BUSINESS WIRE )-- Incyte (Nasdaq: INCY) today ann